Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02271113 · ClinicalTrials.gov registry record · Phase 1
Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects
A Phase 1 study, sponsored by GlycoMimetics Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02271113: Completed Phase 1 study, sponsored by GlycoMimetics Incorporated.
NCT02271113 is a Phase 1 study that has completed, run by GlycoMimetics Incorporated. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02271113, a Phase 1 study, has completed, sponsored by GlycoMimetics Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
In this study, the investigators will evaluate the safety, pharmacokinetics and effect on target biomarkers of coagulation, cell adhesion, and leukocyte and platelet activation of GMI-1271, an E-selectin antagonist, in healthy volunteers.
Interventions
- DRUG Placebo
- DRUG GMI-1271
- DRUG Enoxaparin Sodium (Lovenox®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02271113
The ClinicalTrials.gov registry entry for NCT02271113 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlycoMimetics Incorporated, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02271113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02271113 about?
NCT02271113 is a clinical study titled "Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects". In this study, the investigators will evaluate the safety, pharmacokinetics and effect on target biomarkers of coagulation, cell adhesion, and leukocyte and platelet activation of GMI-1271, an E-selectin antagonist, in healthy volunteers.
What is the current status of trial NCT02271113?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2014-10. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02271113?
The interventions under investigation include: Placebo (DRUG), GMI-1271 (DRUG), Enoxaparin Sodium (Lovenox®) (DRUG).
Who is sponsoring clinical trial NCT02271113?
This trial is sponsored by GlycoMimetics Incorporated, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.